Verition Fund Management
ANIK icon

Verition Fund Management’s Anika Therapeutics ANIK Stock Holding History

Verition Fund Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,802
Closed -$403K – 3624
2025
Q1 		$403K Buy
26,802
+4,885
+22% +$81.3K ﹤0.01% 2713
2024
Q4 		$361K Buy
21,917
+11,970
+120% +$236K ﹤0.01% 2673
2024
Q3 		$246K Sell
9,947
-1,763
-15% -$45.7K ﹤0.01% 2758
2024
Q2 		$297K Buy
+11,710
New +$303K ﹤0.01% 2352
2023
Q4 		– Sell
-16,212
Closed -$302K – 2318
2023
Q3 		$302K Buy
+16,212
New +$336K ﹤0.01% 1729

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return

Verition Fund Management's ANIK Position: Q2 2025 in Review

Verition Fund Management sold out of Anika Therapeutics (ANIK) in Q2 2025, closing a stake of 26,802 shares — an estimated $403K sold.

Verition Fund Management first reported a position in ANIK in Q3 2023 and held it in 5 quarters. The position peaked at $403K in Q1 2025. 103 funds tracked by Wall St. Rank hold ANIK as of Q2 2025.

  • Verition Fund Management reported no remaining Anika Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 26,802 Anika Therapeutics shares in Q2 2025, an estimated $403K.
  • Verition Fund Management first reported a position in Anika Therapeutics in Q3 2023 and held it in 5 quarters.
  • Verition Fund Management's Anika Therapeutics position peaked at $403K in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.